FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319662054> ?p ?o ?g. }

• W4319662054 endingPage "274" @default.
• W4319662054 startingPage "264" @default.
• W4319662054 abstract "Immune checkpoint inhibitors (ICIs) are widely used in the management of patients with advanced urothelial carcinoma (aUC). However, its performance in aUC patients with poor performance status (PS) remains unknown.We aimed to assess the impact of patients' performance status on the oncologic outcomes in patients with aUC treated with ICIs.We searched PubMed, Web of Science, and Scopus from inception until July 2022 to identify studies assessing the association between the Eastern Cooperative Oncology Group (ECOG) PS and the oncologic outcomes in patients with aUC treated with ICIs in randomised (RCTs) and nonrandomised (NRCTs) control studies according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. The outcomes of our interests were overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and objective response rate (ORR).Overall, six RCTs comprising 5428 patients and 32 NRCTs comprising 6069 patients were included. The meta-analysis of the RCTs revealed that patients with ECOG PS = 0 and PS ≥1 had a trend towards better OS with ICIs compared with those treated with chemotherapy (pooled hazard ratio [HR]: 0.86, 95% confidence interval [CI]: 0.71-1.04, and HR: 0.74, 95% CI: 0.53-1.03, respectively). There was no significant difference in terms of response to ICIs between patients with poor and good PS (I2 = 0%, p = 0.46). The meta-analysis of the NRCTs revealed that patients with PS ≥2 had significantly worse OS than those with PS <2 (pooled HR: 2.52, 95% CI: 2.00-3.17), as well as worse CSS (pooled HR: 3.35, 95% CI: 1.90-5.91), PFS (pooled HR: 2.89, 95% CI: 1.67-5.01), and ORR (pooled odds ratio: 0.47, 95% CI: 0.27-0.82). Similarly, patients with PS ≥1 had significantly worse oncologic outcomes than those with PS = 0.In the NRCTs, poor PS was correlated with worse oncologic outcomes in aUC patients treated with ICIs. In the RCTs, ICIs performed better than chemotherapy across all PS categories. These findings should be interpreted with caution due to the high heterogeneity across the studies and patient populations. More RCTs including poor PS are needed to assess the impact of PS on ICI therapy outcomes.Immune therapy for patients with urothelial carcinoma should not be restricted on the grounds of performance status. However, patients with poor performance status should be considered for other factors such as life expectancy and comorbidities." @default.
• W4319662054 created "2023-02-10" @default.
• W4319662054 creator A5002599364 @default.
• W4319662054 creator A5014335753 @default.
• W4319662054 creator A5022306960 @default.
• W4319662054 creator A5028441262 @default.
• W4319662054 creator A5038866794 @default.
• W4319662054 creator A5043690288 @default.
• W4319662054 creator A5044228660 @default.
• W4319662054 creator A5048506098 @default.
• W4319662054 creator A5058063575 @default.
• W4319662054 creator A5066671671 @default.
• W4319662054 creator A5069174563 @default.
• W4319662054 creator A5079401169 @default.
• W4319662054 creator A5080279626 @default.
• W4319662054 creator A5085178415 @default.
• W4319662054 creator A5085983058 @default.
• W4319662054 creator A5087973088 @default.
• W4319662054 date "2023-03-01" @default.
• W4319662054 modified "2023-10-01" @default.
• W4319662054 title "Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis" @default.
• W4319662054 cites W1857682357 @default.
• W4319662054 cites W1981227632 @default.
• W4319662054 cites W2098923148 @default.
• W4319662054 cites W2289712604 @default.
• W4319662054 cites W2559804019 @default.
• W4319662054 cites W2588916311 @default.
• W4319662054 cites W2745624257 @default.
• W4319662054 cites W2760661635 @default.
• W4319662054 cites W2771737095 @default.
• W4319662054 cites W2777192533 @default.
• W4319662054 cites W2802092322 @default.
• W4319662054 cites W2888502795 @default.
• W4319662054 cites W2888599070 @default.
• W4319662054 cites W2930221971 @default.
• W4319662054 cites W2955884544 @default.
• W4319662054 cites W2996343037 @default.
• W4319662054 cites W2999062563 @default.
• W4319662054 cites W3010223451 @default.
• W4319662054 cites W3023823544 @default.
• W4319662054 cites W3024551702 @default.
• W4319662054 cites W3082135257 @default.
• W4319662054 cites W3082744778 @default.
• W4319662054 cites W3086724804 @default.
• W4319662054 cites W3087464965 @default.
• W4319662054 cites W3087466624 @default.
• W4319662054 cites W3087616846 @default.
• W4319662054 cites W3096475149 @default.
• W4319662054 cites W3108137730 @default.
• W4319662054 cites W3119685610 @default.
• W4319662054 cites W3127912627 @default.
• W4319662054 cites W3131288861 @default.
• W4319662054 cites W3139470044 @default.
• W4319662054 cites W3152009817 @default.
• W4319662054 cites W3159010801 @default.
• W4319662054 cites W3159611165 @default.
• W4319662054 cites W3160137056 @default.
• W4319662054 cites W3161584863 @default.
• W4319662054 cites W3164197656 @default.
• W4319662054 cites W3165120554 @default.
• W4319662054 cites W3165772907 @default.
• W4319662054 cites W3166751088 @default.
• W4319662054 cites W3178476179 @default.
• W4319662054 cites W3180083804 @default.
• W4319662054 cites W3180719366 @default.
• W4319662054 cites W3184187052 @default.
• W4319662054 cites W3205704014 @default.
• W4319662054 cites W3208585924 @default.
• W4319662054 cites W3210211517 @default.
• W4319662054 cites W3213374286 @default.
• W4319662054 cites W4211150554 @default.
• W4319662054 cites W4213420312 @default.
• W4319662054 cites W4214609642 @default.
• W4319662054 cites W4220863005 @default.
• W4319662054 cites W4221078360 @default.
• W4319662054 doi "https://doi.org/10.1016/j.euf.2023.01.019" @default.
• W4319662054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36774273" @default.
• W4319662054 hasPublicationYear "2023" @default.
• W4319662054 type Work @default.
• W4319662054 citedByCount "0" @default.
• W4319662054 crossrefType "journal-article" @default.
• W4319662054 hasAuthorship W4319662054A5002599364 @default.
• W4319662054 hasAuthorship W4319662054A5014335753 @default.
• W4319662054 hasAuthorship W4319662054A5022306960 @default.
• W4319662054 hasAuthorship W4319662054A5028441262 @default.
• W4319662054 hasAuthorship W4319662054A5038866794 @default.
• W4319662054 hasAuthorship W4319662054A5043690288 @default.
• W4319662054 hasAuthorship W4319662054A5044228660 @default.
• W4319662054 hasAuthorship W4319662054A5048506098 @default.
• W4319662054 hasAuthorship W4319662054A5058063575 @default.
• W4319662054 hasAuthorship W4319662054A5066671671 @default.
• W4319662054 hasAuthorship W4319662054A5069174563 @default.
• W4319662054 hasAuthorship W4319662054A5079401169 @default.
• W4319662054 hasAuthorship W4319662054A5080279626 @default.
• W4319662054 hasAuthorship W4319662054A5085178415 @default.
• W4319662054 hasAuthorship W4319662054A5085983058 @default.
• W4319662054 hasAuthorship W4319662054A5087973088 @default.
• W4319662054 hasConcept C121608353 @default.

• next